South American Gold Corp. (OTCPK: SAGD)
Health Care · Pharmaceuticals · US
$0.00
— today · 0.0% 1Y
South American Gold Corp. (OTCPK: SAGD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.30K and employs 2 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores South American Gold Corp. across four factors: quality 7/100. Its strongest factor is quality.
SAGD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.30K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -5.02
- Dividend yield
- —
- Beta (5Y)
- 175.86
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.30B
- Employees
- 2
- Next earnings
- —
About South American Gold Corp.
As an operational management entity, South American Gold Corp (SAGD) is dedicated to maximizing shareholder returns. The company achieves this by developing and supplying essential products and support solutions for cannabis-related ventures. Its activities span both innovative technology and established physical goods, ensuring a broad spectrum of products and services.
- ISIN
- US8363012001
- Listed since
- Sep 27, 2010
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.11 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.93 | +0.63% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.78 | +0.15% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.